We’re not just removing the needle.
We’re removing the barrier to better care.

We’re not just removing the needle. We’re removing the barrier to better care.

MOGLU®

Target wearable form factor: 40 x 30 x 16 mm

MOGLU®

Target wearable form factor: 40 x 30 x 16 mm

In an IRB-approved feasibility study with MIT, our prototype achieved 11.34% MARD, with 100% of readings in clinically acceptable Parkes Zones A/B, without needles.

Global patent portfolio

The Most Consistent Accuracy

A low MARD (mean absolute relative difference)
can be misleading without tight data clustering—
consistency matters more than a single number

The Most Consistent Accuracy

A low MARD (mean absolute relative difference) can be misleading without tight data clustering—consistency matters more than a single number.

100% of readings in clinically acceptable Parkes Zones A/B

In Parkes Consensus Error Grid analysis,
all 279 data points fell within Zone A or B.

100% of readings in clinically acceptable Parkes Zones A/B

In Parkes Consensus Error Grid analysis, all 279 data points fell within Zone A or B.

MOGLU®

Target wearable form factor: 40 x 30 x 16 mm

The Most Consistent Accuracy

A low MARD (mean absolute relative difference) can be misleading without tight data clustering—consistency matters more than a single number

100% of readings in clinically acceptable Parkes Zones A/B

In Parkes Consensus Error Grid analysis, all 279 data points fell within Zone A or B.

MOGLU® Highlights

Comfort

Needle-free means

no pain, no irritation.

Accurate

Compact

Affordable

MOGLU® Highlights

Comfort

Needle-free means

no pain, no irritation.

Accurate

Compact

Affordable

MOGLU® Highlights

Comfort

Needle-free means

no pain, no irritation.

Accurate

Compact

Affordable

Comfort

Needle-free means

no pain, no irritation.

Accurate

Compact

Affordable

MOGLU® Highlights

Technology

Reimagining diabetes care
with breakthrough Raman-based sensing.

By targeting a few key wavelengths, we enhance sensitivity
while keeping the device compact and wearable.

No full-spectrum scan required.

Reimagining diabetes care
with breakthrough Raman-based sensing.

By targeting a few key wavelengths, we enhance sensitivity while keeping the device compact and wearable.

No full-spectrum scan required.

Our Team

Our team

Our Team

We build needle-free continuous glucose monitors powered by Raman spectroscopy. Our teams in Boston and Seoul blend deep expertise in optics, engineering, and healthcare to deliver precision solutions for diabetes care.